CD8A and cancer: Clinical translation of CD8-targeted ImmunoPET imaging using a minibody targeting agent, [89Zr]-Df-IAB22M2C, has been further shown to be safe and have favorable kinetics for early monitoring of CD8-rich tissues in cancer patients 33, 34.